BA
GILD icon

BKS Advisors’s Gilead Sciences GILD Stock Holding History

BKS Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,758
Closed -$139K – 200
2016
Q3 		$139K Sell
1,758
-1,200
-41% -$97.5K 0.06% 193
2016
Q2 		$247K Buy
+2,958
New +$263K 0.13% 151

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BKS Advisors's GILD Position: Q4 2016 in Review

BKS Advisors sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 1,758 shares — an estimated $139K sold.

BKS Advisors first reported a position in GILD in Q2 2016 and held it in 2 quarters. The position peaked at $247K in Q2 2016. 1,572 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

  • BKS Advisors reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
  • BKS Advisors sold 1,758 Gilead Sciences shares in Q4 2016, an estimated $139K.
  • BKS Advisors first reported a position in Gilead Sciences in Q2 2016 and held it in 2 quarters.
  • BKS Advisors's Gilead Sciences position peaked at $247K in Q2 2016.
  • 1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on BKS Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.